novo nordisk patent semaglutide Takes Telehealth Company to Court Over Knockoffs What is the patent landscape

Retatrutide is a peptide agonist with an extended half-life (~6 days), allowing for weekly subcutaneous administration

professor and division head of endocrinology, diabetes and clinical nutrition

By supplementing your endogenous supply of peptides with exogenous sources, you provide your body with more of the resources it needs to carry out specific functions

This is the first step in being able to use someones genetic make-up to help us improve that decision-making process. This work represents the first detailed look at GLP-1 resistance, although its underlying cause is still unknown

Final Thoughts Your semaglutide is a valuable medication and a key part of your health journey